Mastheads zilico on glass
Logo

Zilico Limited

Developing the next generation of cancer diagnostics - objective, accurate, and delivers results in real-time, helping extend screening programmes globally

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Manchester, England, GB
  • Currency GBP
  • Founded February 2006
  • Employees 8
  • Incorporation Type Other
  • Website zilico.co.uk

Company Summary

Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time. These characteristics allow for the improvement of clinical screening programmes, globally. The product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) platform technology. EIS is a scientifically-proven method to differentiate between normal, pre cancerous and cancerous tissues.

Team

  • Default avatar
    Sameer Kothari
    Chief Executive

    Sameer brings over 20 years commercial experience. Prior to joining Zilico in Nov 2007 Sameer was CEO of Plasso Technology Ltd, a venture capital-backed company developing research tools and labware for the life sciences. 2007 saw the launch of its first product, EpranEx. In May 2007, Sameer successfully led a trade sale exit of Plasso to Becton Dickinson Inc. Prior to joining Plasso, he was a senior executive within Marconi plc.

  • Default avatar
    Peter Highfield
    Technical Director

    Peter has over 30 years experience in industrial R&D, particularly product development, and has worked in the diagnostics and biotechnology markets. He has held senior management or director level positions in Wellcome Diagnostics, Murex Diagnostics and Tepnel Life Sciences. Latterly, Peter worked with Sameer as Head of Life Sciences at Plasso Technology Ltd until the company was acquired.

  • Default avatar
    Brian Brown
    Academic Founder

    Brian’s main research interests are the practical realization of Electrical Impedance Tomography (EIT) and Tissue Spectroscopy (EIS) as routine clinical tools. He pioneered the development of EIT and initiated European Union Concerted Action Programmes in this field. He has contributed to about 250 scientific publications and patents and also to several books. Brian is based at the University of Sheffield and Sheffield Teaching Hospitals.

  • Default avatar
    John Tidy
    Clinical Founder

    John is Consultant Gynaecologist at the Royal Hallamshire Hospital, Sheffield. He is a certified colposcopist and a recognised specialist in gynaecological cancer surgery. He has a proven track record in clinical research attracting funding from Cancer Research UK, World Cancer Research Fund International, NHS New and Emerging Technologies Programme and the Pharmaceutical Industry. John has published in high profile peer review medical scientific

  • Default avatar
    Andrew Saipe
    Commercial Director

    With 20 years in the medical sales industry, Andrew joined Zilico from Purple Surgical where he was an International Sales Manager for 8 years responsible for a number of markets throughout Europe & the rest of the World. Prior to that he was with Covidien in sales a role

Advisors

  • Default avatar
    DLA Piper LLP
    Lawyer
    Unconfirmed
    Default avatar
    PWC LLP
    Unconfirmed

Previous Investors